Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Research Commentary

Letter regarding Xiao WZ et al. entitled “Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis”

Authors: Weichuan Dai, Junyan Chen, Xieli Guo, Zhaozhi Su

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

With great interest, we read the article “Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis” (by Xiao et al. Tumor Biol 35(7):6687–6693, 2014), which has reached important conclusions that the phosphatase and tensin homolog (PTEN) gene mutations were closely related to poor prognosis of glioma patients. Through quantitative analysis, the investigators (Xiao WZ et al.) showed that glioma patients with PTEN gene mutations exhibited a significantly shorter overall survival (OS) than those without PTEN gene mutations (HR = 3.66, 95 % CI = 2.02∼5.30, P < 0.001). Ethnicity-stratified subgroup analysis demonstrated that PTEN gene mutations were closely linked to poor prognosis in glioma among Americans (HR = 3.72, 95 % CI = 1.72∼5.73, P < 0.001), while similar correlations were not observed among populations in Sweden, Italy, and Malaysia (all P > 0.05). The meta-analysis results are encouraging. Nevertheless, some deficiencies still existed that we would like to raise.
Literature
1.
go back to reference Xiao WZ, Han DH, Wang H, et al. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumor Biol. 2014;35(7):6687–93.CrossRef Xiao WZ, Han DH, Wang H, et al. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumor Biol. 2014;35(7):6687–93.CrossRef
Metadata
Title
Letter regarding Xiao WZ et al. entitled “Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis”
Authors
Weichuan Dai
Junyan Chen
Xieli Guo
Zhaozhi Su
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3481-4

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine